Lonidamine (AF-1890) 是一种己糖激酶 (hexokinase) 和丙酮酸载体 (mitochondrial pyruvate carrier) 抑制剂 (Ki: 2.5 μM)。Lonidamine 还可抑制癌细胞中的有氧糖酵解。Lonidamine 可用于线粒体代谢和炎症的研究,如肺纤维化。
生物活性 | Lonidamine (AF-1890) is ahexokinaseandmitochondrial pyruvate carrierinhibitor (Ki: 2.5 μM). Lonidamine also inhibits aerobic glycolysis incancercells. Lonidamine can be used in the research ofmitochondrial metabolismand inflammation, such as pulmonary fibrosis[1][2][3]. |
IC50& Target | Ki: 2.5 μM (Mitochondrial pyruvate carrier)[2] |
体外研究 (In Vitro) | Lonidamine (100 μM, 24 h) inhibits TGF-β-stimulated lactate production and oxygen consumption rate in AKR-2B and TIG-1 cells[3]. Lonidamine (100 μM, 24/48 h) inhibits H2030BrM3 and A549 cell proliferation[4]. Lonidamine (100-200 μM, 24 h) inhibits H2030BrM3 and A549 cell invasion[4]. Lonidamine (100-1000 μM, 24 h) inhibits mitochondrial complex I and II activities[4]. Lonidamine (200 μM, 24 h) increases ROS generation in H2030BrM3 lung cancer cells[4].
|
体内研究 (In Vivo) | Lonidamine (oral administration, 10-100 mg/kg/day, d10 to d20) improves lung function by inhibiting hexokinase 2 (HK2) activity in BLM-induced pulmonary fibrosis murine model[3].
Animal Model: | Lonidamine (oral administration, 10-100 mg/kg/day, d10 to d20) improves lung function by inhibiting hexokinase 2 (HK2) activity in BLM-induced pulmonary fibrosis murine model[3].
| Dosage: | 10, 30, 100 mg/kg/day | Administration: | Oral administration, daily, d10 to d20 after BLM treatment. | Result: | Partially or completely reversed the increases in HK2 and lactate induced by BLM and reduced the expression of 10 profibrotic mediators. |
|
Clinical Trial | |
分子量 | |
性状 | |
Formula | |
CAS 号 | |
中文名称 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Powder | -20°C | 3 years | | 4°C | 2 years | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
溶解性数据 | In Vitro: DMSO : 50 mg/mL(155.69 mM;Need ultrasonic) 配制储备液 1 mM | 3.1137 mL | 15.5686 mL | 31.1371 mL | 5 mM | 0.6227 mL | 3.1137 mL | 6.2274 mL | 10 mM | 0.3114 mL | 1.5569 mL | 3.1137 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.08 mg/mL (6.48 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (6.48 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2.08 mg/mL (6.48 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (6.48 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|